In CLL, there are multiple trials of interest being presented with the potential to have an impact on practice, including the phase III Alliance North American Intergroup Study A041202 exploring ibrutinib alone or in combination with rituximab vs standard chemoimmunotherapy with bendamustine plus rituximab for untreated patients 65 years of age or older; the phase III iLLUMINATE trial comparing the chemotherapy-free combination regimen of ibrutinib plus obinutuzumab vs chlorambucil plus obinutuzumab in the frontline setting, including for high-risk populations; and a late-breaking abstract on the phase III ECOG-ACRIN Cancer Research Group trial E1912 evaluating combination therapy with ibrutinib plus rituximab vs standard chemoimmunotherapy for untreated patients aged younger than 70 years.
#####
I hope these are all enhancements to current care standards for our community.Rob
